EP1196156A4 - Compositions anticonvulsives transnasales et processus module - Google Patents

Compositions anticonvulsives transnasales et processus module

Info

Publication number
EP1196156A4
EP1196156A4 EP00947610A EP00947610A EP1196156A4 EP 1196156 A4 EP1196156 A4 EP 1196156A4 EP 00947610 A EP00947610 A EP 00947610A EP 00947610 A EP00947610 A EP 00947610A EP 1196156 A4 EP1196156 A4 EP 1196156A4
Authority
EP
European Patent Office
Prior art keywords
modulated process
compositions
transnasal anticonvulsive
transnasal
anticonvulsive compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00947610A
Other languages
German (de)
English (en)
Other versions
EP1196156A2 (fr
EP1196156B1 (fr
Inventor
Yong Wong Choi
Lianli Li
Kwon-Ho Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Inc
Original Assignee
SK Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Corp filed Critical SK Corp
Publication of EP1196156A2 publication Critical patent/EP1196156A2/fr
Publication of EP1196156A4 publication Critical patent/EP1196156A4/fr
Application granted granted Critical
Publication of EP1196156B1 publication Critical patent/EP1196156B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP00947610A 1999-07-26 2000-07-24 Compositions anticonvulsives transnasales Expired - Lifetime EP1196156B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14559099P 1999-07-26 1999-07-26
US145590P 1999-07-26
PCT/US2000/020119 WO2001006987A2 (fr) 1999-07-26 2000-07-24 Compositions anticonvulsives transnasales et processus module

Publications (3)

Publication Number Publication Date
EP1196156A2 EP1196156A2 (fr) 2002-04-17
EP1196156A4 true EP1196156A4 (fr) 2005-01-12
EP1196156B1 EP1196156B1 (fr) 2008-04-30

Family

ID=22513768

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00947610A Expired - Lifetime EP1196156B1 (fr) 1999-07-26 2000-07-24 Compositions anticonvulsives transnasales

Country Status (16)

Country Link
US (2) US6627211B1 (fr)
EP (1) EP1196156B1 (fr)
JP (1) JP4951723B2 (fr)
KR (1) KR100715513B1 (fr)
CN (1) CN1200697C (fr)
AR (1) AR031072A1 (fr)
AT (1) ATE393626T1 (fr)
AU (1) AU778896B2 (fr)
CA (1) CA2379365C (fr)
DE (1) DE60038738T2 (fr)
ES (1) ES2304969T3 (fr)
MX (1) MXPA02001612A (fr)
MY (1) MY124195A (fr)
RU (1) RU2264209C2 (fr)
TW (1) TWI269652B (fr)
WO (1) WO2001006987A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038738T2 (de) * 1999-07-26 2009-07-02 Sk Holdings Co., Ltd. Transnasale anticonvulsive zusammensetzungen
CA2529489C (fr) * 2003-06-17 2012-01-03 Sk Corporation Microemulsions transnasales contenant de la diazepame
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
RS51269B (sr) * 2004-09-16 2010-12-31 Janssen Pharmaceutica N.V. Upotreba 2-fenil-1,2-etandiol-(di)karbamata za tretiranje epileptogeneze
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
SI1933809T1 (sl) * 2005-10-11 2012-08-31 Yissum Res Dev Co Sestavki za mazalno dajanje
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
EP2121025B1 (fr) * 2007-01-19 2016-11-02 Hananja Ehf Procédés et compositions pour l'administration d'un agent thérapeutique
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
JP2010526822A (ja) * 2007-05-07 2010-08-05 クエスター ファーマシューティカルズ，インク． ベンゾジアゼピン類の経鼻投与
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2030610A1 (fr) * 2007-08-31 2009-03-04 Archimedes Development Limited Compositions pharmaceutiques non aqueuses
WO2009027697A2 (fr) * 2007-08-31 2009-03-05 Archimedes Development Limited Compositions pharmaceutiques non aqueuses
US8507468B2 (en) * 2007-10-02 2013-08-13 Robert Orr Intranasal anti-convulsive compositions and methods
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
CN103619338B (zh) * 2011-03-31 2016-06-22 阿索尔达治疗有限公司 鼻内苯并二氮杂卓药物组合物
EP2694076A4 (fr) * 2011-04-01 2014-08-27 Cpex Pharmaceuticals Inc Formulations nasales de benzodiazépine
WO2012174158A2 (fr) 2011-06-14 2012-12-20 Hale Biopharma Ventures, Llc Administration de benzodiazépine
CN102836125A (zh) * 2011-06-23 2012-12-26 王晓青 治疗低血容量休克的丙戊酸及其盐的鼻腔给药制剂
JP2015227288A (ja) * 2012-08-31 2015-12-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 けいれん重積発作の治療用医薬組成物
US20160000803A1 (en) * 2013-02-22 2016-01-07 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for transmucosal administration of benzodiazepines
WO2017085687A1 (fr) 2015-11-20 2017-05-26 West-Ward Pharmaceuticals International Limited Formulation stable de phénobarbital sodique pour injection
EP3681474A1 (fr) 2017-09-11 2020-07-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions et procédés pour l'administration nasale de médicaments en direction du cerveau et en vue d'un effet systémique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016929A1 (fr) * 1990-05-10 1991-11-14 Novo Nordisk A/S PREPARATION PHARMACEUTIQUE CONTENANT DES n-GLYCOFUROLS ET DES n-ETHYLENE GLYCOLS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2573275B2 (ja) * 1986-03-10 1997-01-22 ブルグハルト，クルト 薬学的製剤及びその製造法
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
DE60038738T2 (de) * 1999-07-26 2009-07-02 Sk Holdings Co., Ltd. Transnasale anticonvulsive zusammensetzungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016929A1 (fr) * 1990-05-10 1991-11-14 Novo Nordisk A/S PREPARATION PHARMACEUTIQUE CONTENANT DES n-GLYCOFUROLS ET DES n-ETHYLENE GLYCOLS

Also Published As

Publication number Publication date
DE60038738T2 (de) 2009-07-02
JP4951723B2 (ja) 2012-06-13
DE60038738D1 (de) 2008-06-12
US7132112B2 (en) 2006-11-07
EP1196156A2 (fr) 2002-04-17
AU6118500A (en) 2001-02-13
US6627211B1 (en) 2003-09-30
TWI269652B (en) 2007-01-01
EP1196156B1 (fr) 2008-04-30
ES2304969T3 (es) 2008-11-01
AR031072A1 (es) 2003-09-10
AU778896B2 (en) 2004-12-23
MXPA02001612A (es) 2003-10-14
RU2002104970A (ru) 2004-01-10
RU2264209C2 (ru) 2005-11-20
WO2001006987A3 (fr) 2002-01-24
KR20020059583A (ko) 2002-07-13
MY124195A (en) 2006-06-30
KR100715513B1 (ko) 2007-05-08
CN1364079A (zh) 2002-08-14
US20040028617A1 (en) 2004-02-12
ATE393626T1 (de) 2008-05-15
WO2001006987A2 (fr) 2001-02-01
JP2003505403A (ja) 2003-02-12
CN1200697C (zh) 2005-05-11
CA2379365A1 (fr) 2001-02-01
CA2379365C (fr) 2009-11-17

Similar Documents

Publication Publication Date Title
EP1196156A4 (fr) Compositions anticonvulsives transnasales et processus module
ZA200110022B (en) Thiazoloderivatives and pharmaceutical compositions containing them.
GB9903584D0 (en) Modified calycins
AU7651100A (en) Pharmaceutical and/or cosmetical compositions
PT1317256E (pt) Composição farmacêutica com veículo modificado
GB9906245D0 (en) Enzyme
GB0318112D0 (en) ›-Secretase enzyme compositions and methods
GB9914798D0 (en) Ensure
GB2349646B (en) Two-part cleansing composition
PL356157A1 (en) Pharmaceutical and/or cosmetical compositions
AU7447600A (en) Antiobestic agents
HUP0201960A3 (en) Bleaching and disinfecting composition
AU4993000A (en) Waste treatment composition
IL139428A0 (en) Perfumes
AU1057401A (en) Pancreatitis remedies
GB9908458D0 (en) Enzyme
AU3347300A (en) Desmethylsildenafil compositions and methods
GB9920242D0 (en) Swab
GB9929310D0 (en) Semiochemical
GB9916506D0 (en) Compositions and methods
GB9921747D0 (en) Compositions and methods
GB9916503D0 (en) Compositions and methods
GB9928549D0 (en) Compositions and methods
GB9902051D0 (en) Compositions and methods
GB9912409D0 (en) Compounds and compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020205

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041130

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 9/00 B

Ipc: 7A 61K 31/045 A

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5513 20060101ALI20070220BHEP

Ipc: A61K 31/165 20060101AFI20070220BHEP

Ipc: A61K 9/10 20060101ALI20070220BHEP

Ipc: A61K 9/08 20060101ALI20070220BHEP

Ipc: A61P 25/08 20060101ALI20070220BHEP

RTI1 Title (correction)

Free format text: TRANSNASAL ANTICONVULSIVE COMPOSITIONS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LI, LIANLI

Inventor name: KIM, KWON-HO

Inventor name: CHOI, YONG-MOON

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SK CORPORATION

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SK HOLDINGS CO., LTD.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REF Corresponds to:

Ref document number: 60038738

Country of ref document: DE

Date of ref document: 20080612

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MOINAS & SAVOYE SA

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080930

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080430

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080430

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2304969

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080430

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

26N No opposition filed

Effective date: 20090202

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080724

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080731

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20110616

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20110801

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60038738

Country of ref document: DE

Representative=s name: HANNKE BITTNER & PARTNER, DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: SK BIOPHARMACEUTICALS CO., LTD

Free format text: SK HOLDINGS CO., LTD.#99 SEORIN-DONG JONGRO-GU#SEOUL 110-110 (KR) -TRANSFER TO- SK BIOPHARMACEUTICALS CO., LTD#99, SEORIN DONG, JONGRO-GU#SEOUL 110-110 (KR)

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20120216 AND 20120222

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60038738

Country of ref document: DE

Representative=s name: HANNKE BITTNER & PARTNER, DE

Effective date: 20120131

Ref country code: DE

Ref legal event code: R081

Ref document number: 60038738

Country of ref document: DE

Owner name: SK BIOPHARMACEUTICALS CO., LTD., KR

Free format text: FORMER OWNER: SK HOLDINGS CO., LTD., SEOUL, KR

Effective date: 20120131

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: SK BIOPHARMACEUTICALS CO., LTD., KR

Effective date: 20120220

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: SK BIOPHARMACEUTICALS CO., LTD.

Effective date: 20120409

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20120731

Year of fee payment: 13

Ref country code: GB

Payment date: 20120731

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20120831

Year of fee payment: 13

Ref country code: ES

Payment date: 20120829

Year of fee payment: 13

Ref country code: FR

Payment date: 20120814

Year of fee payment: 13

Ref country code: IT

Payment date: 20120725

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20121001

Year of fee payment: 13

BERE Be: lapsed

Owner name: SK BIOPHARMACEUTICALS CO., LTD.

Effective date: 20130731

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20130724

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130724

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140201

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130725

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60038738

Country of ref document: DE

Effective date: 20140201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130724

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130725